Fintel reports that on October 13, 2025, BTIG maintained coverage of Zimmer Biomet Holdings (NYSE:ZBH) with a Buy ...

Zimmer Biomet is undervalued despite recent underperformance, backed by innovation, acquisitions, and strong cash flow. Learn ...

Investors with an interest in Medical - Products stocks have likely encountered both Zimmer Biomet (ZBH) and EssilorLuxottica Unsponsored ADR (ESLOY). But which of these two companies is the best ...

Fintel reports that on October 7, 2025, Evercore ISI Group maintained coverage of Zimmer Biomet Holdings (NYSE:ZBH) with a In ...

Zimmer Biomet is set to post its third-quarter results next month, and analysts project a single-digit earnings rise.

Zimmer (ZBH) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

This MoneyShow Chart of the Day shows the 2-year/30-year US Treasury spread. That’s the difference between the yield on the 2-year Treasury Note and the yield on the 30-year Treasury Bond. You can see ...

Indexes careened through jarring swings as worries built about the financial health of small and midsized banks, as well as the souring U.S.-China trade relationship. Bank stocks steadied themselves ...

Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $114.0, with a high estimate of $130.00 and a low estimate of $96.00. Observing a 5.88% ...

Zimmer Biomet (NYSE: ZBH) announced yesterday that it launched two new solutions for complex foot and ankle trauma.

Zimmer Biomet (NYSE: ZBH) + Zimmer Biomet Holdings, Inc. $98.85 1.92% Open 98.935 Day High 101.083 52 Week High 133.6 52 Week ...